{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:56:43Z","timestamp":1792699003694,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cancer antigen 125 (CA125) is a widely used biomarker in monitoring of epithelial ovarian cancer (EOC). Due to insufficient cancer specificity of CA125, its diagnostic use is severely compromised. Abnormal glycosylation of CA125 is a unique feature of ovarian cancer cells and could improve differential diagnosis of the disease. Here we describe the development of a quantitative lateral flow immunoassay (LFIA) of aberrantly glycosylated CA125 which is widely superior to the conventional CA125 immunoassay (CA125IA). With a 30\u2009min read-out time, the LFIA showed 72% sensitivity, at 98% specificity using diagnostically challenging samples with marginally elevated CA125 (35\u2013200\u2009U\/mL), in comparison to 16% sensitivity with the CA125IA. We envision the clinical use of the developed LFIA to be based on the substantially enhanced disease specificity against the many benign conditions confounding the diagnostic evaluation and against other cancers.<\/jats:p>","DOI":"10.1038\/s42003-020-01191-x","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T10:44:26Z","timestamp":1598006666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Glycovariant-based lateral flow immunoassay to detect ovarian cancer\u2013associated serum CA125"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7458-4630","authenticated-orcid":false,"given":"Sherif","family":"Bayoumy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-3654","authenticated-orcid":false,"given":"Heidi","family":"Hyyti\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Leivo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-9530","authenticated-orcid":false,"given":"Sheikh M.","family":"Talha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9685-5246","authenticated-orcid":false,"given":"Kaisa","family":"Huhtinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8953-1734","authenticated-orcid":false,"given":"Matti","family":"Poutanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0854-7225","authenticated-orcid":false,"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1413-6414","authenticated-orcid":false,"given":"Antti","family":"Perheentupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpo","family":"Lamminm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Gidwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-5591","authenticated-orcid":false,"given":"Kim","family":"Pettersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"1191_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/bios5030577","volume":"5","author":"S Sharma","year":"2015","unstructured":"Sharma, S., Zapatero-Rodr\u00edguez, J., Estrela, P. & O\u2019Kennedy, R. Point-of-care diagnostics in low resource settings: present status and future role of microfluidics. Biosensors 5, 577\u2013601 (2015).","journal-title":"Biosensors"},{"key":"1191_CR2","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/ijms20040952","volume":"20","author":"M Lisio","year":"2019","unstructured":"Lisio, M., Fu, L., Goyeneche, A., Gao, Z. & Telleria, C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int. J. Mol. Sci. 20, 952 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"1191_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"1191_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1470-2045(11)70333-3","volume":"13","author":"L Gilbert","year":"2012","unstructured":"Gilbert, L. et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project. Lancet Oncol. 13, 285\u2013291 (2012).","journal-title":"Lancet Oncol."},{"key":"1191_CR5","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","volume":"387","author":"IJ Jacobs","year":"2016","unstructured":"Jacobs, I. J. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945\u2013956 (2016).","journal-title":"Lancet"},{"key":"1191_CR6","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamainternmed.2018.0591","volume":"178","author":"SA Narod","year":"2018","unstructured":"Narod, S. A. Is there a future for ovarian cancer screening? JAMA Intern. Med. 178, 611\u2013612 (2018).","journal-title":"JAMA Intern. Med."},{"key":"1191_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1089\/mab.2014.0017","volume":"33","author":"T Michurina","year":"2014","unstructured":"Michurina, T., Kerzhner, M. & Klimovich, B. Development and characterization of three novel monoclonal antibodies against CA-125. Monoclon. Antib. Immunodiagn. Immunother. 33, 319\u2013324 (2014).","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"1191_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1021\/pr3010474","volume":"12","author":"K Chen","year":"2013","unstructured":"Chen, K. et al. Microarray glycoprofiling of CA125 improves differential diagnosis of ovarian cancer. J. Proteome Res. 12, 1408\u20131418 (2013).","journal-title":"J. Proteome Res."},{"key":"1191_CR9","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1074\/mcp.M113.037085","volume":"13","author":"M Anugraham","year":"2014","unstructured":"Anugraham, M. et al. Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status. Mol. Cell. Proteom.: MCP 13, 2213\u20132232 (2014).","journal-title":"Mol. Cell. Proteom.: MCP"},{"key":"1191_CR10","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","volume":"57","author":"JM Escudero","year":"2011","unstructured":"Escudero, J. M. et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin. Chem. 57, 1534\u20131544 (2011).","journal-title":"Clin. Chem."},{"key":"1191_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/diagnostics7010014","volume":"7","author":"FR Ueland","year":"2017","unstructured":"Ueland, F. R. A perspective on ovarian cancer biomarkers: past, present and yet-to-come. Diagnostics 7, 14 (2017).","journal-title":"Diagnostics"},{"key":"1191_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1158\/1940-6207.CAPR-11-0053","volume":"4","author":"PL Mai","year":"2011","unstructured":"Mai, P. L., Wentzensen, N. & Greene, M. H. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev. Res. 4, 303\u2013306 (2011).","journal-title":"Cancer Prev. Res."},{"key":"1191_CR13","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/bjc.2017.222","volume":"117","author":"U Menon","year":"2017","unstructured":"Menon, U. et al. The cost-effectiveness of screening for ovarian cancer: Results from the UK collaborative trial of ovarian cancer screening (UKCTOCS). Br. J. Cancer 117, 619\u2013627 (2017).","journal-title":"Br. J. Cancer"},{"key":"1191_CR14","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1021\/pr500215g","volume":"13","author":"L Marcos-Silva","year":"2014","unstructured":"Marcos-Silva, L. et al. Characterization of binding epitopes of CA125 monoclonal antibodies. J. Proteome Res. 13, 3349\u20133359 (2014).","journal-title":"J. Proteome Res."},{"key":"1191_CR15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1159\/000012003","volume":"57","author":"M Lundin","year":"1991","unstructured":"Lundin, M. et al. Sialyl tn is a frequently expressed antigen in colorectal cancer: no correlation with patient prognosis. Oncology 57, 70\u201376 (1991).","journal-title":"Oncology"},{"key":"1191_CR16","doi-asserted-by":"publisher","first-page":"10231","DOI":"10.1073\/pnas.172380699","volume":"99","author":"S Hakomori","year":"2002","unstructured":"Hakomori, S. Glycosylation defining cancer malignancy: New wine in an old bottle. Proc. Natl Acad. Sci. USA 99, 10231 (2002).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1191_CR17","doi-asserted-by":"publisher","first-page":"15636","DOI":"10.3390\/ijms140815636","volume":"14","author":"R Saldova","year":"2013","unstructured":"Saldova, R. et al. Exploring the glycosylation of serum CA125. Int. J. Mol. Sci. 14, 15636\u201315654 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"1191_CR18","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1097\/IGC.0b013e3182473292","volume":"22","author":"K Akita","year":"2012","unstructured":"Akita, K. et al. Different levels of sialyl-tn antigen expressed on MUC16 in patients with endometriosis and ovarian cancer. Int. J. Gynecologic Cancer 22, 531\u2013538 (2012).","journal-title":"Int. J. Gynecologic Cancer"},{"key":"1191_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.14748\/bmr.v25.1050","volume":"25","author":"R Sheta","year":"2014","unstructured":"Sheta, R. & Bachvarov, D. Role of aberrant glycosylation in ovarian cancer dissemination. Biomed. Rev. 25, 83 (2014).","journal-title":"Biomed. Rev."},{"key":"1191_CR20","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1373\/clinchem.2016.257691","volume":"62","author":"K Gidwani","year":"2016","unstructured":"Gidwani, K. et al. A nanoparticle-lectin immunoassay improves discrimination of serum CA125 from malignant and benign sources. Clin. Chem. 62, 1390\u20131400 (2016).","journal-title":"Clin. Chem."},{"key":"1191_CR21","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1373\/jalm.2018.028266","volume":"4","author":"K Gidwani","year":"2019","unstructured":"Gidwani, K. et al. Europium nanoparticle-based sialyl-tn monoclonal antibody discriminates epithelial ovarian Cancer\u2013Associated CA125 from benign sources. J. Appl. Lab. Med. 4, 299\u2013310 (2019).","journal-title":"J. Appl. Lab. Med."},{"key":"1191_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/diagnostics8020039","volume":"8","author":"B Hayes","year":"2018","unstructured":"Hayes, B., Murphy, C., Crawley, A. & O\u2019Kennedy, R. Developments in point-of-care diagnostic technology for cancer detection. Diagnostics 8, 39 (2018).","journal-title":"Diagnostics"},{"key":"1191_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-240-3","volume-title":"Lateral Flow Immunoassay","author":"RC Wong","year":"2009","unstructured":"Wong, R. C. Lateral Flow Immunoassay. (Springer, New York, 2009)."},{"key":"1191_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ab.2012.06.005","volume":"428","author":"E Juntunen","year":"2012","unstructured":"Juntunen, E., Myyryl\u00e4inen, T., Salminen, T., Soukka, T. & Pettersson, K. Performance of fluorescent europium (III) nanoparticles and colloidal gold reporters in lateral flow bioaffinity assay. Anal. Biochem. 428, 31\u201338 (2012).","journal-title":"Anal. Biochem."},{"key":"1191_CR25","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jim.2018.12.001","volume":"465","author":"T Salminen","year":"2019","unstructured":"Salminen, T., Juntunen, E., Talha, S. M. & Pettersson, K. High-sensitivity lateral flow immunoassay with a fluorescent lanthanide nanoparticle label. J. Immunol. Methods 465, 39\u201344 (2019).","journal-title":"J. Immunol. Methods"},{"key":"1191_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s10895-005-2825-7","volume":"15","author":"T Soukka","year":"2005","unstructured":"Soukka, T., Kuningas, K., Rantanen, T., Haaslahti, V. & L\u00f6vgren, T. Photochemical characterization of upconverting inorganic lanthanide phosphors as potential labels. J. Fluorescence 15, 513\u2013528 (2005).","journal-title":"J. Fluorescence"},{"key":"1191_CR27","doi-asserted-by":"publisher","first-page":"3811","DOI":"10.1002\/anie.200705861","volume":"47","author":"T Rantanen","year":"2008","unstructured":"Rantanen, T., J\u00e4rvenp\u00e4\u00e4, M.\u2010L., Vuojola, J., Kuningas, K. & Soukka, T. Fluorescence\u2010quenching\u2010based enzyme\u2010activity assay by using photon upconversion. Angew. Chem. Int. Ed. 47, 3811\u20133813 (2008).","journal-title":"Angew. Chem. Int. Ed."},{"key":"1191_CR28","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1021\/ac001287l","volume":"73","author":"T Soukka","year":"2001","unstructured":"Soukka, T., H\u00e4rm\u00e4, H., Paukkunen, J. & L\u00f6vgren, T. Utilization of kinetically enhanced monovalent binding affinity by immunoassays based on multivalent nanoparticle-antibody bioconjugates. Anal. Chem. 73, 2254\u20132260 (2001).","journal-title":"Anal. Chem."},{"key":"1191_CR29","doi-asserted-by":"crossref","unstructured":"Salminen, L. et al. A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high-grade serous ovarian cancer. Gynecol. Oncol. 156, 689\u2013694 (2019).","DOI":"10.1016\/j.ygyno.2019.12.025"},{"key":"1191_CR30","doi-asserted-by":"publisher","first-page":"100831","DOI":"10.1016\/j.mam.2019.11.001","volume":"72","author":"K Gidwani","year":"2020","unstructured":"Gidwani, K. et al. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results. Mol. Asp. Med. 72, 100831 (2020).","journal-title":"Mol. Asp. Med."},{"key":"1191_CR31","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000217982","volume":"17","author":"K Nustad","year":"1996","unstructured":"Nustad, K. et al. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol. 17, 196\u2013219 (1996).","journal-title":"Tumour Biol."},{"key":"1191_CR32","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.21105\/joss.01686","volume":"4","author":"H Wickham","year":"2019","unstructured":"Wickham, H. et al., Welcome to the tidyverse. J. Open Source Softw. 4, 1686, https:\/\/doi.org\/10.21105\/joss.01686 (2019).","journal-title":"J. Open Source Softw."},{"key":"1191_CR33","unstructured":"Kassambara, A. ggpubr: \u2018ggplot2\u2019 Based Publication Ready Plots. R package version 0.1. 7. [cited 2020 Jan 08]. Available from: https:\/\/CRAN.R-project.org\/package=ggpubr."},{"key":"1191_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77","volume":"12","author":"X Robin","year":"2011","unstructured":"Robin, X. et al. pROC: An open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinforma. 12, 77 (2011).","journal-title":"BMC Bioinforma."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01191-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01191-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T02:49:42Z","timestamp":1670381382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-020-01191-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["1191"],"URL":"https:\/\/doi.org\/10.1038\/s42003-020-01191-x","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}